Indegene (NSE:INDGN) Debt-to-Revenue : 0.03 (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Indegene Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Indegene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹292 Mil. Indegene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹724 Mil. Indegene's annualized Revenue for the quarter that ended in Mar. 2025 was ₹30,224 Mil. Indegene's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.03.

Indegene Debt-to-Revenue Historical Data

The historical data trend for Indegene's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indegene Debt-to-Revenue Chart

Indegene Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

Debt-to-Revenue

0.05

0.04

0.22

0.19

0.04

Indegene Quarterly Data
	Mar21	Mar22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Revenue	Get a 7-Day Free Trial						0.18	-	0.03	-	0.03

Competitive Comparison of Indegene's Debt-to-Revenue

For the Health Information Services subindustry, Indegene's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indegene's Debt-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Indegene's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Indegene's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Indegene Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Indegene's Debt-to-Revenue for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(292	+	724)	/	28393
	=	0.04

Indegene's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(292	+	724)	/	30224
	=	0.03

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.

Indegene Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Indegene's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Indegene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Indegene Ltd (NSE:INDGN) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

544172:India

Address

Outer Ring Road, Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Nagawara, Bengaluru, KA, IND, 560045

Website

https://www.indegene.com

Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment.

Indegene Headlines

No Headlines